Navigation Links
Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
Date:9/9/2008

Third PharmacoSurgery(TM) Platform Product Candidate in Clinical Trials

SEATTLE, Sept. 9 /PRNewswire/ -- Omeros Corporation today announced that it is enrolling patients in a Phase 1/Phase 2 study of OMS302, the Company's third PharmacoSurgery(TM) product candidate, for use during ophthalmologic surgery. At least 60 patients undergoing age-related cataract extraction with lens replacement are planned for enrollment in the study.

"With the initiation of this study, all three of Omeros' current PharmacoSurgery product candidates are now in the clinic," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Each of the two agents in OMS302 is currently used individually and perioperatively during eye surgery. OMS302 combines these two agents and their pharmacologic activities into a single proprietary product candidate. With approximately three million cataract procedures performed annually in the U.S. alone, OMS302 is designed to address a large and growing market."

The Phase 1/Phase 2 trial is a randomized, double-blind, vehicle-controlled and parallel-assigned study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. OMS302 is added to standard irrigation solutions used in ophthalmologic surgery and is delivered directly to the eye during the operation.

PharmacoSurgery(TM) product candidates are proprietary combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. The lead product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is currently in two Phase 3 clinical programs evaluating its safety and ability to improve postoperative joint function and reduce pain following arthroscopic surgery. The urological PharmacoSurgery
'/>"/>

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
2. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
3. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
4. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
5. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... has announced the addition of the ... to their offering.      (Logo: ... been broadly classified into wide categories based ... for the treatment of different gynecological conditions ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... Sept. 19, 2014 Research and Markets ... (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast ... the purposes of this report, the human microbiome market is ... human microbiome market is expected to be valued as $294 ... CAGR of 22.3% within the forecast period of 2019-2023. The ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... Johnson & Johnson Pharmaceutical,Research & Development, L.L.C., ... as effective as commonly used combination,therapy in ... by a,broad spectrum of bacteria. Ceftobiprole also ... of patients who had infections caused by ...
... surgeon-to-surgeon communication leads to more ... results in Stabilimax NZ study, DURANGO, Colo. ... premier developer of collaborative innovation networks, today announced,that ... facilitate a,clinical study for Applied Spine,s Stabilimax NZ(R) ...
Cached Medicine Technology:New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA 2New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA 3New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA 4Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System 2Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System 3
(Date:9/22/2014)... California (PRWEB) September 22, 2014 Plugin ... of ProSparkle. A fully customizable 3D particle emitter made ... “Adding the ProSparkle particle emitter plugin to a video ... Christina Austin, CEO of Pixel Film Studios. “ProSparkle gives ... described as cool” , With ProSparkle users are given ...
(Date:9/22/2014)... 2014 The Ruby Report was launched ... PWN International Conference in Louisville, Kentucky. This release followed ... with a reception attended by 60 people from the ... she had gained while conducting her research, what drove ... ceiling issue, and what she believes companies can do ...
(Date:9/21/2014)... of an infant prior to 37 weeks of pregnancy ... over the past two decades. According to the ... affects nearly 500,000 babies each year, or one of ... has improved survival rates for preterm infants, questions remain ... preterm infants. , Research led by Barry M. Lester, ...
(Date:9/21/2014)... 21, 2014 Hastings and Hastings, a ... record demand for aggressively discounted accident victim attorney’s fees. ... the Valley each year, it is more important than ... discounted attorney’s fees as a way to enjoy more ... has been a frontrunner when it comes to delivering ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProSparkle Particle Emitter Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2
... Beach, OPEN TO MEDIA; Also ... to Discuss ,The Future of National Drug Policy, Intervention, ... It According to HHS; In ... Lack Treatment, PALM BEACH, Fla., Sept. 25 Four Star General,Barry McCaffrey ...
... Cross and Blue,Shield Association (BCBSA) was recently recognized, separately, ... supports the careers,of new employees and encourages the continued ... one of the "Best Places to Launch,a Career" and ... "AARP Best,Employers for Workers Over 50" designation. BusinessWeek ...
... Sept. 25 The leading Republican,presidential contenders have stood ... they also appear to be standing behind his threat,to ... to,know: Would Rudy Giuliani, John McCain, Mitt Romney and ... will likely pass today?, The bill came up ...
... treatment, experts say , TUESDAY, Sept. 25 (HealthDay News) ... a sign of early Alzheimer,s disease, U.S. researchers report. ... become available, spotting the disease early will become critical. ... in Durham, N.C., used functional magnetic resonance imaging (fMRI) ...
... , , TUESDAY, Sept. 25 (HealthDay News) -- People newly ... normal incidence of colorectal tumors and cancers, a study ... and the heart disease "probably develop through the mechanism ... the University of Hong Kong that,s published in the ...
... 25 AstraZeneca (NYSE:,AZN), a global leader in ... "100 Best Companies" to work for by Working ... that recognizes the company,s commitment,to work-life balance, retention ... extensive benefits designed to keep its employees,happy and ...
Cached Medicine News:Health News:4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, & Country's Top Drug Treatment CEO Barry Karlin to Keynote Palm Beach, FL National 'Moment Of Change' Intervention Conference: 2Health News:Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees 2Health News:Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees 3Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 2Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 3Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 4Health News:Brain Activity Might Point to Early Alzheimer's 2Health News:Study Links Coronary Disease, Colon Cancer 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: